You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. High-throughput nanoMEA-based Proarrhythmia Assay

    SBC: CURI BIO, INC.            Topic: NHLBI

    PROJECT SUMMARY Failure of new drugs at late stages of development is an extremely costly event commonly associated with the detection of unexpected arrhythmogenic properties in novel drugs Undetected arrhythmia inducing effects are also a common reason for drug withdrawal from the market As a result the FDA now mandates that all new drugs be tested for potential arrhythmogenic properties which ha ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing

    SBC: TWINSTRAND BIOSCIENCES INC            Topic: 102

    Nearly a quarter of a million new cases of ovarian cancer are identified every year worldwide and the majority of these woman will die from their disease. When detected early, surgical cure rates exceed 90%, but currently most cases are detected at an advanced stage when the cancer has already disseminated. As such, our most pressing problem in ovarian cancer is a lack of tools to identify early s ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. An Automated Early Motor Development Risk Screener from Observational Video Recordings of Infants and Toddlers

    SBC: BSOLUTIONS, INC.            Topic: NICHD

    Motor development plays a pivotal role in an infant’s overall development and has a cascading effect on social, cognitive, memory, and language ability. These functions can be compromised when motor development is disrupted; motor disruption is associated with generalized developmental delays. Early screening and identification of delays can allow early interventions with the goal of not just im ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThere is an urgentunmet need for novel therapeutic approaches that are efficacious against lung cancerRanking first among cancer deaths in the U Sthis disease hasyear relative survival rates of andltMost lung cancers are non small cellNSCLCof casesCurative surgery is not an option for theof NSCLC patients who present with advanced stage III cancerFor these patients chemo radiation therapy ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Sleeping Beauty Engineered B Cells for Mucopolysaccharidosis

    SBC: IMMUSOFT CORP            Topic: 300

    Project Summary Mucopolysaccharidosis type IMPS Iis an autosomal recessive storage disease caused by the absence ofL iduronidaseIDUAresulting in systemic accumulation of glycosaminoglycanGAGstorage materialshepatosplenomegalyskeletal dysplasiascardiopulmonary obstructionprogressive neurologic impairment and death by ageMPS I is currently treated by enzyme replacement therapy and by allogeneic hema ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A Computer Model of Renal Physiology for use as a FDA Medical Device Development Tool

    SBC: HC SIMULATION LLC            Topic: FDA

    The purpose of this proposal is to develop a validated physiological model of the human physiologyespecially the cardio renal axisfor submission to the FDA Medical Device Development Tool pilot programThe model will be used to aid in the development and regulation of medical devices designed to treat hypertensionExamples include devices for renal nerve ablationelectrical stimulation of the carotid ...

    SBIR Phase II 2018 Department of Health and Human ServicesFood and Drug Administration
  7. Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine

    SBC: ORLANCE, INC            Topic: NIAID

    Abstract There is a growing consensus that protection against HIV infection will require BOTH antiviral antibody responses as well as polyfunctional CDand CDT cells with potent lytic activityTo stimulate the breadthpotencyand rate of response requiredProfectus Biosciences intends to utilize its platform technologies based on DNA vaccines combined with genetic adjuvantsAs a step in that directiona ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer

    SBC: PRECYTE INC            Topic: 102

    Project Summary. The Indicator Cell Assay Platform (iCAP) is an inexpensive blood-based assay that can be used for early detection of disease, disease stage stratification, prognosis and response to therapy for a variety of diseases. The iCAP uses cultured, standardized cells as biosensors, capitalizing on the ability of cells to respond to disease signals present in serum with exquisite sensitivi ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma

    SBC: Syntrix Biosystems, Inc.            Topic: 102

    The chemokine receptors CXCR1 and CXCR2 (CXCR1/2) are validated as having essential roles in the growth, survival, motility, invasion and angiogenesis of human melanoma, which secretes abundant amounts of the corresponding chemokine ligands, including CXCL8. Additionally, abnormal cancer-induced immunosuppressive myeloid-derived suppressor cells (MDSCs) in the circulation and tumor correlate with ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government